{"id":"physioneal-40","safety":{"commonSideEffects":[{"rate":null,"effect":"Peritonitis"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Electrolyte imbalances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Physioneal 40 is a balanced peritoneal dialysis solution containing 40 mmol/L of bicarbonate buffer and lactate, designed to reduce peritoneal inflammation and improve biocompatibility compared to conventional dialysates. The solution uses glucose as the osmotic agent to drive fluid removal while the buffering system helps maintain peritoneal pH and reduce glucose degradation products that can accumulate during dwell time.","oneSentence":"Physioneal 40 is a peritoneal dialysis fluid that facilitates ultrafiltration and solute removal in patients with renal failure by creating an osmotic gradient across the peritoneal membrane.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:00:24.660Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"End-stage renal disease requiring peritoneal dialysis"}]},"trialDetails":[{"nctId":"NCT03994471","phase":"PHASE3","title":"Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.","status":"RECRUITING","sponsor":"Iperboreal Pharma Srl","startDate":"2022-12-14","conditions":"End Stage Renal Disease","enrollment":170},{"nctId":"NCT00567489","phase":"PHASE4","title":"IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients","status":"COMPLETED","sponsor":"Vantive Health LLC","startDate":"2008-01","conditions":"ESRD, Diabetes, CAPD","enrollment":137},{"nctId":"NCT00567398","phase":"PHASE3","title":"IMPENDIA- PEN VS Dianeal Only Improved Metabolic Control In Diabetic CAPD and APD Patients","status":"COMPLETED","sponsor":"Vantive Health LLC","startDate":"2008-04","conditions":"ESRD, Diabetes","enrollment":43},{"nctId":"NCT00776191","phase":"PHASE4","title":"Randomized Multicenter Cross-over Study to Compare the Effect of Physioneal 35 to 40 on the Protein Metabolism","status":"TERMINATED","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2008-09","conditions":"Endstage Renal Disease","enrollment":5}],"_emaApprovals":[],"_faersSignals":[{"count":372,"reaction":"DEATH"},{"count":60,"reaction":"PERITONITIS BACTERIAL"},{"count":57,"reaction":"PERITONITIS"},{"count":42,"reaction":"SEPSIS"},{"count":36,"reaction":"CARDIAC ARREST"},{"count":33,"reaction":"PERITONEAL DIALYSIS COMPLICATION"},{"count":32,"reaction":"CARDIAC FAILURE"},{"count":30,"reaction":"PNEUMONIA"},{"count":29,"reaction":"COVID-19"},{"count":29,"reaction":"MYOCARDIAL INFARCTION"}],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nephropaed-PD-01/B"],"phase":"marketed","status":"active","brandName":"Physioneal 40","genericName":"Physioneal 40","companyName":"University of Erlangen-Nürnberg Medical School","companyId":"university-of-erlangen-n-rnberg-medical-school","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Physioneal 40 is a peritoneal dialysis fluid that facilitates ultrafiltration and solute removal across the peritoneal membrane during peritoneal dialysis treatment. Used for End-stage renal disease requiring peritoneal dialysis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}